New technologies for the radiotherapy of prostate cancer

Frontiers of Radiation Therapy and Oncology

Volumn 40, Issue , 2007, Pages 315-337

  Meyer, J L ^a   Leibel, S ^b   Roach, M ^c   Vijayakumar, S ^d  

^a Saint Francis Memorial Hospital   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER; COMPUTER ASSISTED RADIOTHERAPY; CONFERENCE PAPER; HUMAN; IMPOTENCE; INTENSITY MODULATED RADIATION THERAPY; MALE; METHODOLOGY; PROSTATE TUMOR; RADIATION DOSE; RADIATION EXPOSURE; RECTUM;

HUMANS; IMPOTENCE; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; URINARY BLADDER;

EID: 34547548651     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: 10.1159/0000106044     Document Type: Conference Paper

References (21)

1. Roach M 3rd, Faillace-Akazawa P, Malfatti C: Prostate volumes and organ movement defined, by serial computerized tomographic scans during three-dimensional conformal radiotherapy. Radiat Oncol Investig 1997;5:187-194.
2. Millender LE, Aubin M, Pouliot J, Shinohara K, Roach M 3rd: Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized, prostate cancer. Int J Radiat Oncol Biol Phys 2004;59:6-10.
3. Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS: Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined and-rogen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003;21:1904-1911.
4. Roach M, DeSilvio M, Thomas CR, Valicenti R, Asbell SO, Lawton C, Shipley WS: Progression-free survival (PFS) after whole-pelvic (WP) vs mini-pelvic (MP) or prostate-only (PO) radiotherapy (RT): a subset analysis of RTOG 9413, a phase III prospective randomized trial using neoadjuvant and concurrent hormone therapy (N&CHT). Int J Radiat Oncol Biol Phys 2004;60: S264-S265.
5. Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein. BE, Hunt MA: Dose escalation with 3D conformal treatment: five-year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998;41: 501-510.
6. Fisch BM, Pickett B, Weinberg V, Roach M 3rd: Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer. Urology 2001;57:955-959.
7. Roach M, Winter K, Michalski JM, Cox JD, Purdy JA, Bosch W, Lin X, Shipley WS: Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys 2004;60:1351-1356.
8. Ryu J, Winter K, Michalski J, Purdy J, Markoe, A, Earle J, Perez, Roach M, Sandler H, Cox J, Pollack A: Preliminary report of toxicity following 3D conformal radiation therapy (3DCRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys 2001;51:136-137.
9. Kuban D, Pollack A, Huang E, Levy L, Dong L, Starkschall G, Rosen I: Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:1260-1268.
10. Koper PC, Jansen P, van Putten W, van Os M, Wijnmaalen AJ, Lebesque JV, Levendag PC: Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial. Radiother Oncol 2004;73:1-9.
11. Michalski JM, Winter K, Purdy JA, Perez CA, Ryu JK, Parliament MB, Valicenti RK, Roach M 3rd, Sandler HM, Markoe AM, Cox JD: Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level. IV. Int J Radiat Oncol Biol Phys 2004;58:735-742.
12. Zapatero A, Garcia-Vicente F, Modolell I, Alcantara P, Floriano A, Cruz-Conde A, Torres JJ, Perez-Torrubia A: Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect. Int J Radiat Oncol Biol Phys 2004;59:1343-1351.
13. Leibel SA, Kutcher GJ, Zelefsky MJ, Burman CM, Mohan R, Ling CC, Fuks Z: 3-D conformai radio-therapy for carcinoma of the prostate. Clinical experience at the Memorial Sloan-Kettering Cancer Center. Front Radiat Ther Oncol 1996;29:229-237.
14. Zelefsky JM, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Venkatraman ES, Leibel SA: High-dose radiation delivered by intensity-modulated conformal radio-therapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-881.
15. Leibel SA, Fuks Z, Zelefsky MJ, Whitmore WF: The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 1994;28:7-16.
16. Brenner DJ: Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 2004;60:1013-1015.
17. Zelefsky MJ, Fuks Z, Happersett L, Lee L, Ling CC, Burman CM, Hunt M, Wolfe T, Venkatraman ES, Jackson A, Skwarchuk M, Leibel SA: Clinical experience with intensity-modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000;55:241-249.
18. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amoils H, Venkatraman ES, Leibel SA: High-dose intensity-modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111-1118.
19. Levegrun S, Jackson A, Zelefsky MJ, Venkatraman. ES, Skwarchuk MW, Schlegel W, Fuks Z, Leibel SA, Ling CC: Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol 2002;63;11-26.
20. Vicini FA, Martinez A, Hanks G, Hanlon A, Miles B, Kernan K, Beyers D, Ragde H, Forman J, Fontanesi J, Kestin L, Kovacs G, Denis L, Slawin K, Scardino P: An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 2002:95:2126-2135.
21. Hahn PF, Deserno WM, Tabatabaei S, van de Kaa. CH, de la Rosette J, Weissleder R: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348: 2491-2499.